Clinical trial · Observational
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
NCT02565017CI-TRIAL-00045667completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best chemotherapy choices for their patients. The investigators will conduct focus groups with cancer patients who have received chemotherapy treatment at MSK in order to understand cancer patients' thoughts about IBM Watson Oncology.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Focus groups | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Breast Cancer
- description
- and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
- interventionNames
- Behavioral: Focus groups
- label
- Lung Cancer
- description
- and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
- interventionNames
- Behavioral: Focus groups
- label
- Colorectal Cancer
- description
- and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * MSKCC patient 18 years or older * Breast, lung, or colorectal cancer MSK patient as per EMR or clinician judgment having either: * Chemotherapeutic adjuvant or neoadjuvant treatment with the first chemo visit occurring within the past 8 months and primary treatment (i.e., surgery), occurring within the past 6 months)at MSK * OR chemotherapeutic treatment for metastatic disease with the first chemo visit occurring within the past 8 months at MSK * OR chemotherapeutic treatment through an on-going MSK clinical trial as per clinician * Residing in New York metro-area Exclusion Criteria: * Non-English speakers because we do not have the resources to conduct and translate the focus groups into other languages * Patients who are not or will not receive their cancer care at MSKCC. * Patient unwilling or unable to provide informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.